Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 9/20 | 0.54 |
| ▸ | MTTP | P55157 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 6/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL4396683 | 0.98 | MTTP (0.52) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3289542 | 0.94 | MAPT (0.48) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3289635 | 0.93 | APOB (0.48) | APOBMTTPSMO | |
| SCHEMBL3288902 | 0.93 | EPHX1 (0.46) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3288874 | 0.93 | APOB (0.45) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3289783 | 0.93 | SMO (0.46) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3289592 | 0.92 | APOB (0.47) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3290031 | 0.92 | APOB (0.45) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3289658 | 0.92 | APOB (0.45) | APOBMTTPNPC1RAB9ASMO | |
| SCHEMBL3295229 | 0.91 | NPC1 (0.50) | APOBMTTPNPC1RAB9ASMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753721-B1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GMBH (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | claimed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1753721-B1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1753721-A1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121091-A1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GMBH (DE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | APOB 23/4885MTTP 202/4885NPC1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.